American College of Cardiology

Journalists: please note that all presentations are embargoed until the time of their actual presentation at the Late Breaking Clinical Trial (LBCT) sessions. The date and time of each official presentation at an LBCT session is provided at the end of each trial topic description.

Highlights from:

SUNDAY | MONDAY | TUESDAY | WEDNESDAY

SUNDAY, MARCH 17
Results from Sunday

7:40 a.m. - 8:45 a.m.
ACC Opening Media Briefing

Presenters: ACC President Dr. Douglas P. Zipes, ACC '02 Program Committee Chair Dr. Eric S. Williams, and ACC '02 Program Committee Co-chair Dr. John M. Miller of Indiana University School of Medicine, Indianapolis.

  Listen to the news conference.

10:30 a.m. - 11:15 a.m.
Percutaneous Coronary Intervention General

• A Double-Blind, Placebo-Controlled, Randomized Trial of Fluvastatin After Successful Percutaneous Intervention (PCI) in Patients With Coronary Heart Disease: The Lescol Intervention Prevention Study (LIPS)—Patrick W. Serruys, MD, FACC, Erasmus University, Rotterdam, Netherlands, 3/20, 8:30 a.m., #421
• Impact of Clinical Syndrome Acuity on the Differential Response to Two Glycoprotein IIb/IIIa Inhibitors on Patients Undergoing Coronary Stenting: The TARGET Trial—Gregg W. Stone, MD, FACC, Lenox Hill Heart and Vascular Institute, New York, NY, 3/17, 5:15 p.m., #0032-6
• Early and Sustained Survival Benefit Associated With Statin Therapy at the time of Percutaneous Coronary Intervention—Albert W. Chan, MD, The Cleveland Clinic Foundation, Cleveland, Ohio, 3/17, 3:00 p.m., #1053-1
• Emergency CABG After Failed PCI in Contemporary Practice: A Report From the ACC-NCDR™ Registry—Lloyd W. Klein, MD, FACC, St. Luke's Medical Center, Chicago, Illinois, 3/18, 3:00 p.m., #1125-7

Moderator: George Ventrovec, MD, FACC, Medical College of Virginia
  Listen to the news conference.

11:30 a.m. - 12:15 p.m.
Percutaneous Coronary Intervention Coated Stents

• Safety and Feasibility of a Tacrolimus-Coated Drug-Eluting Stent: Short- and Mid-Term Results of a Tacrolimus-Coated Drug-Eluting Stent: Short- and Mid-Term Results of Both the PRESENT and the EVIDENT Trial—Peter Fitzgerald, MD, FACC, Stanford, Calif., 3/17, 8:45 a.m., #22 (speaker not present)
• Heparin-Coated Stents in Small Coronary Arteries: Results of the COAST Trial—Michael Haude, MD, Med.Klinik II, UKL, Essen, Germany, 3/17, 8:45 a.m., #22
• 210-Day Follow-up of the RAVEL Study: A Randomized Study with the Sirolimus-Eluting Bx VELOCITY™ Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions—Jean Fajadet, MD, Clinique Pasteur, Toulouse, France, 3/17, 4:00 p.m., #0032-1
• Late (Two-Year) Follow-Up From the First-in-Man (FIM) Experience After Impantation of Sirolimus-Eluting Stents—Jose Eduardo Sousa, MD, FACC, Institute Dante Pazzanese of Cardiology, San Paulo, Brazil, 3/17, 4:30 p.m., #0032-3
• Sirolimus-Eluting Stents Abolish Neointimal Hyperplasia in Patients With In-Stent Restenosis: Late Angiographic and Intravascular Ultrasound Results—Patrick W. Serruys, MD, FACC, Erasmus University, Rotterdam, Netherlands, 3/18, 2:00 p.m., #823-1
• Safety and Performance of a Paclitaxel-Eluting Stent for the Treatment of In-Stent Restenosis: Preliminary Results of the Taxus III Trial—Gregg W. Stone, MD, FACC, Lenox Hill Heart and Vascular Institute, New York, NY, 3/19, 12:00 p.m., #1174-15
• Oral Sirolimus for Recalcitrant In-Stent Restenosis—Paul S. Teirstein, MD, FACC, Scripps Clinic, La Jolla, Calif., 3/18, 2:30 p.m., #823-3

Moderator: Spencer King, MD, MACC, Cardiology of Georgia, Atlanta
  Listen to the news conference.

MONDAY, MARCH 18
Results from Monday

8:15 a.m. - 9:00 a.m.
Heart Failure

• Cardiac Resynchronization Therapy Reduces Morbidity in Patients With Moderate to Severe Systolic Heart Failure and Intraventricular Conduction Delays—William T. Abraham, MD, FACC, University of Kentucky, Lexington, Kentucky, 3/18, 4:15 p.m., #839-2
• Cardiac Resynchronization Reverses Left Ventricular Remodeling and Reduces Cytokine Activation in Patients With Dilated Cardiomyopathy and Left Bundle Branch Block—William T. Abraham, MD, FACC, University of Kentucky, Lexington, Kentucky, 3/17, 10:00 a.m., #1017-119
• Upgrade to Biventricular Pacing in Advanced Heart Failure Patients Previously Implanted With a Conventional Pacemaker for a Classical Indication: Is It Worth It?—Jean-Claude Daubert, Chu Pontchaillou Centre Cariopn, Rennes, France, 3/18, 11:30 a.m., #815-3
• Effects of the Endothelin Receptor Antagonist Bosentan on the Morbidity and Mortality in Patients With Chronic Heart Failure: Results of the ENABLE 1 and 2 Trial Program—Milton Packer, MD, FACC, Columbia Presbyterian Medical Center, New York, NY, 3/19, 8:30 a.m., #412

Moderator: Sharon Hunt, MD, FACC, Stanford University Medical Center, Palo Alto, Calif.
  Listen to the news conference.

11:00 a.m. – 11:45 a.m.
Prevention and Treatment of Atrial Fibrillation

• Survival in Patients Presenting With Atrial Fibrillation: The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study—George Wyse, MD, PhD, FACC, University of Calgary, Canada, 3/18, 9:15 a.m., #405
• Rate Control vs. Electrical Cardioversion for Persistent Atrial Fibrillation. A Randomized Comparison of Two Treatment Strategies Concerning Mortality and Morbidity: The RACE Study—Harry J. Crijins, MD, FESC, University Hospital Maastrict, Netherlands, 3/18, 9:15 a.m., #405
• Focal vs. Isolation Ablation of Pulmonary Vein Triggers for Atrial Fibrillation: Short-Term Outcome—Francis E. Marchlinski, MD, FACC, University of Pennsylvania, Philadelphia, PA, 3/20, 9:45 a.m., #885-6
• Pulmonary Veins Isolation for Treatment of Atrial Fibrillation in Patients With Impaired Left Ventricular Function—Nassir F. Marrouche, MD, The Cleveland Clinic Foundation, Cleveland, Ohio, 3/20, 9:00 a.m., #885-3

Moderator: Anne Curtis, MD, FACC, University of Florida, Gainesville, Fla.
  Listen to the news conference.

12:00 p.m. – 12:45 p.m.
Diabetes

• Exposure to Glitazone Antidiabetics and Risk of Heart Failure Among Persons With Type 2 Diabetes: A Retrospective Population-Based Cohort Analysis—Mr. Thomas Delea, Policy Analysis, Inc., Brookline, Mass., 3/19, 11:00 a.m., #858-3
• Dramatic Increase in 30-Day Mortality in Diabetic Patients With Non-ST Segment Elevation Acute Coronary Sydromes—Marco Roffi, MD, Cleveland Clinic Foundation, Cleveland, Ohio, 3/19, 9:15 a.m., #840-4
• Improving Outcome in Treatment of Diabetics With ST Elevation Myocardial Infarction: Insights from the GUSTO Trials—Hitinder S. Gurm, MD, Cleveland Clinic Foundation, Cleveland, Ohio, 3/18, 10:00 a.m., #1074-33
• Make the Link! patient survey results—John Buse, MD, PhD, CDE, FACC, University of North Carolina School of Medicine,Chapel Hill, on behalf of the American Diabetes Association

Moderator: Robert Rosenson, MD, FACC, University of Florida, Gainesville, Fla.
  Listen to the news conference.

1:45 p.m. – 2:30 p.m.
ACCardio Unveiled at ACC'02

Presenters:

• Shahir Kassam-Adams, Elsevier Science, Inc., Health Sciences Division, New York City
• Kim A. Eagle, MD, FACC, University of Michigan Medical Center, Ann Arbor, Mich.

Moderator: Douglas P. Zipes, MD, FACC, Krannert Institute of Cardiology, Indianapolis
  Listen to the news conference.

TUESDAY, MARCH 19
Results from Tuesday

7:30 a.m. - 8:15 a.m.
Heart Disease Risk Factors and Prevention

• The National Cholesterol Education Program Guidelines Underestimate Disease Risk in Young Adults—Paul M. Schoenfeld, MD, FACC, Gundersen Clinic, Las Crosse, Wisc., 3/19, 12:00 p.m., #1179-76
• The Metabolic Score Predicts Subclinical Atherosclerosis Independent of Fasting Serum LDL: Evidence Supporting Inclusion of the Metabolic Syndrome as a Component Within the NCEP ATP III Guidelines —Marc E. Hunt, MD, Walter Reed Army Medical Center, Washington, D.C., 3/19, 12:00 p.m., #1179-77
• Adult High Density Lipoprotein Cholesterol Has Decreased Ten Percent in the Past 25 Years: The Princeton Follow-Up Study—John A. Morrison, MD, Children's Hospital, Cincinnati, Ohio, 3/19, 12:00 p.m., #1179-78
• Echocardiography Predicts Early Cardiovascular Risk in a Population of Normal Young Adult Women—Thomas Kimball, MD, Children's Hospital, Cincinnati, Ohio, 3/17, 4:36 p.m., #1062MP-129
• Body Composition and Prognosis in Chronic Systolic Heart Failure: The Obesity Paradox—Carl J. Lavie, MD, FACC, Ochsner Medical Institutions, New Orleans, La., 3/19, 2:45 p.m., #869-4

Moderator: Richard Pasternak, MD, FACC, Massachusetts General Hospital, Boston, Mass.
  Listen to the news conference.

10:30 a.m. - 11:15 a.m.
Blood Markers—B-Type Natriuretic Peptide

• A Prospective, Blinded Trial of B-Type Natriuretic Peptide as a Diagnosis Test for the Emergency Diagnosis of Heart Failure: The Breathing Not Properly (BNP) Multinational Study—Peter A. McCullough, MD, MPH, FACC, Truman Medical Center, Kansas City, Mo., 3/19, 8:30 a.m., #412
• Primary Results of the BNP Multinational Study: B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure—Alan S. Maisel, MD, FACC, San Diego VA Healthcare, La Jolla, CA., 3/17, 11:45 a.m., #895-6
• Plasma N-Terminal pro-BNP Predicts the Occurrence of Major Clinical Events in Severe Chronic Heart Failure: Results of a Substudy of the COPERNICUS Trial—Franz S. Hartmann, MD, Medical Klinik II, UKL, Germany, 3/20, 10:30 a.m., #895-1
• Echocardiography Predicts Early Cardiovascular Risk in a Population of Normal Young Adult Women—Thomas Kimball, MD, Children's Hospital, Cincinnati, Ohio, 3/17, 4:36 p.m., #1062MP-129
• Body Composition and Prognosis in Chronic Systolic Heart Failure: The Obesity Paradox—Carl J. Lavie, MD, FACC, Ochsner Medical Institutions, New Orleans, La., 3/19, 2:45 p.m., #869-4

Moderator: Margaret Redfield, MD, FACC, Mayo Clinic, Rochester, Minn.
  Listen to the news conference.

11:30 a.m. - 12:15 p.m.
Quality of Care

• Effectiveness of Quality Improvement Initiative (Guidelines Applied to Practice [GAP] Project) in Improving the Care of Medicare Patients and Women With Acute Myocardial Infarction—Rajendra H. Mehta, MD, University of Michigan Health System, Ann Arbor, Mich., 3/19, 9:15 a.m., #849-4
• Is Early Hospital Discharge Following Acute Myocardial Infarction Associated With Increased Mortality?—Alan K. Berger, MD, University of Minnesota, Minneapolis, Minn., 3/19, 8:45 a.m., #861-1
• Quality of Care of Patients Admitted With Congestive Heart Failure: Influence of Physician Specialty and Hospital Type—Jay K. Amin, MD, University of Michigan, Ann Arbor, 3/19, 8:45 a.m., #849-2
• Is Quality of Life Enhanced in Octogenarians Undergoing Coronary Artery Bypass Surgery?—Paul Kurlansky, MD, FACC, Miami Heart Research Institute, Miami, Fla., 3/19, 9:00 a.m., #847-3

Moderator: Raymond J. Gibbons, MD, FACC, Nuclear Cardiology Lab, Mayo Clinic, Rochester, Minn.
  Listen to the news conference.

12:30 p.m. - 1:15 p.m.
Defibrillators

• Improved Survival With Prophylactic ICD Therapy in Patients With Prior Myocardial Infarction and Reduced Left Ventricular Ejection Fraction—Arthur J. Moss, MD, FACC, University of Rochester Medical Center, Rochester, N.Y., 3/19, 8:30 a.m., #412
• Results of the InSync ICD Clinical Trial—James B. Young, MD, FACC, The Cleveland Clinic Foundation, Cleveland, Ohio, 3/20, 8:30 a.m., #421
• New Therapeutic Option for Patients With Time-Dependent Risk of Sudden Cardiac Arrest: Application of Novel Wearable Cardioverter-Defibrillator—Arthur M. Feldman, MD, PhD, FACC, University of Pittsburgh School of Medicine, Pittsburgh, Pa., 3/18, 2:00 p.m., #826-1
• Flight Attendant Response to AED Instruction: Results of a Survey and Implications for Training Public Access Defibrillation—Richard L. Page, MD, FACC, University of Texas Southwestern Medical Center, Dallas, Texas, 3/17, 10:00 a.m., #1003-33
• Early Defibrillation Training Courses for Lay Volunteers Without Cardiopulmonary Resuscitation Education: The Piacenza Progetto Vita Experience—Alessandro Capucci, MD, FACC, Ospedale Clinic, Piacenza, Italy, 3/17, 10:00 a.m., #1003-37
• Broad Dissemination of Automatic External Defibrillators Triples Sudden Cardiac Arrest Survival in a Medium-Size Town—Alessandro Capucci, MD, FACC, Ospedale Clinic, Piacenza, Italy, 3/19 4:15 p.m., #870-2

Moderator: Douglas P. Zipes, MD, FACC, ACC president and Indiana University School of Medicine, Indianapolis, Indiana
  Listen to the news conference.

WEDNESDAY, MARCH 20
Results from Wednesday

7:30 a.m. - 8:15 a.m.
Gender, Age, and Race

• Gregg W. Stone, MD, FACC, Lenox Hill Heart and Vascular Institute, New York, N.Y., Primary Stenting Optimizes the Outcome of Women With Acute Myocardial Infarction: Results From the CADILLAC Trial (3/18, 2:15 p.m., #824FO-2)
• Milton Packer, MD, FACC, Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)
• Matthias Pfisterer, MD, FACC, University Hospital, Basel, Switzerland, Outcome of Elderly Women With Refractory Chronic Angina Treated Invasively Versus Medically: Comparison With Elderly Men in the Prospective Randomized Trial of Invasive Versus Medical Therapy in the Elderly (TIME) (3/19, 9:45 a.m., #847-6)
  
• Marc S. Sabatine, MD, Brigham & Women’s Hospital, Boston, Mass., Nonwhite Race Is Associated With a Higher Rate of Death and Ischemic Complications in Patients With Acute Coronary Syndromes Despite Modern Early Invasive Treatment (3/19, 8:30 a.m., #840-1)

Moderator: C. Noel Bairey Merz, MD, FACC, Cedar-Sinai Medical Center, Los Angeles, Calif.
  Listen to the news conference.